Worldwide Differences in Regulations of Clozapine Use

  title={Worldwide Differences in Regulations of Clozapine Use},
  author={Jimmi Nielsen and Corina Young and Petru Ifteni and Taishiro Kishimoto and Yutao Xiang and Peter F J Schulte and Christoph U. Correll and David Taylor},
  journal={CNS Drugs},
Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US… 

A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology

Rational use requires modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, the use of clozAPine levels for personalizing dosing, and theUse of slow and personalized titration to make clozabine as safe as possible and contribute to increased life expectancy and well-being.

Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use

Clozapine remains the only treatment indicated in TRS, but it is dramatically underutilized and efforts must be implemented that ensure its use in this population while maximizing safety.

The Modernization of Clozapine

There is an urgent need for advancing technology used for clozapine monitoring, evaluating barriers created by REMS, and establishing consistent practices throughout the US.

Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19

Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available and the genetic vulnerability postulates predictors of adverse reactions’ severity; patients with a lower genetic risk could have less frequent hematological monitoring.

Analysis of Clozapine Use and Safety by Using Comprehensive National Data From the Japanese Clozapine Patient Monitoring Service

The data obtained in this study will enable the optimal and safe use of clozapine in Japanese patients with treatment-resistant schizophrenia and enable the incidence of clazapine-induced adverse events to be reduced.

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.

This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration, and slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia).

Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.

While clozapine remains an underused medication, the new FDA monitoring guidelines are likely to substantially reduce the percentage of patients who meet criteria for clozAPine-associated hematologic events requiring treatment interruption, which may reduce the clinical burden of managing patients on clozabine and therefore increase the number of individuals treated with this uniquely effective medication.

Frequency of neutropenia over time in patients on clozapine

A contrast is found between the relatively high density of the confirmed red results at the beginning of clozapine treatment which significantly reduces after 6 months of treatment which remained low thereafter.



Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.

In 2 of the 3 studied side effects, diabetic ketoacidosis and gastrointestinal hypomotility, reduction of mortality to the level of agranulocytosis is both necessary and feasible, and the screening guidelines for serious side effects with clozapine need to be modified.

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

The estimated impact of the CNR on clozapine-related morbidity and mortality over the first 5 years of commercial experience in the United States is reviewed.

Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

Substantial delays to clozapine initiation remain and antipsychotic polypharmacy and high doses are commonly used prior to clazapine, despite treatment guidelines.

Clozapine: more than 900 mg/day may be needed

Clinicians should be alert to the possibility of treatment failure because of rapid clozapine clearance secondary to genetic factors and heavy cigarette consumption, notably in young male smokers and anyone given relatively high-dose clozAPine (600 mg/day or more) should be monitored regularly for adverse events.

Clozapine Use in Australia

Clozapine is a well-recognized treatment for treatment-resistant schizophrenia and should be initiated in patients who do not respond adequately to trials of at least two different antipsychotics including one non-clozAPine second generation antipsychotic.

An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels

Compared to Caucasian patients, Asian patients appeared to have a lower dosage requirement for clinical efficacy, and appropriate dose adjustment should be considered in Asian patients receiving maintenance clozapine therapy in clinical practice.

Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial

Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?

Results suggest that prompt discontinuation of clozapine without rechallenge is indicated for agranulocytosis, myocarditis, cardiomyopathy, and a QTc interval > 500 milliseconds that is confirmed and derived using the appropriate correction method.